These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 23397148

  • 21. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial.
    Weinblatt ME, Westhovens R, Mendelsohn AM, Kim L, Lo KH, Sheng S, Noonan L, Lu J, Xu Z, Leu J, Baker D, Bingham CO, GO-FURTHER investigators.
    Ann Rheum Dis; 2014 Dec; 73(12):2152-9. PubMed ID: 24001888
    [Abstract] [Full Text] [Related]

  • 22. Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis.
    Tanaka Y, Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, Koike T.
    Int J Rheum Dis; 2020 Mar; 23(3):316-324. PubMed ID: 31957303
    [Abstract] [Full Text] [Related]

  • 23. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
    Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT.
    Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
    [Abstract] [Full Text] [Related]

  • 24. Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis.
    Keystone EC, Pope JE, Thorne JC, Poulin-Costello M, Phan-Chronis K, Vieira A, Haraoui B, CAMEO Investigators.
    Rheumatology (Oxford); 2016 Feb; 55(2):327-34. PubMed ID: 26361879
    [Abstract] [Full Text] [Related]

  • 25. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial.
    Weinblatt ME, Bingham CO, Mendelsohn AM, Kim L, Mack M, Lu J, Baker D, Westhovens R.
    Ann Rheum Dis; 2013 Mar; 72(3):381-9. PubMed ID: 22661646
    [Abstract] [Full Text] [Related]

  • 26. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis.
    Wiland P, Dudler J, Veale D, Tahir H, Pedersen R, Bukowski J, Vlahos B, Williams T, Gaylord S, Kotak S.
    J Rheumatol; 2016 Jul; 43(7):1268-77. PubMed ID: 27252426
    [Abstract] [Full Text] [Related]

  • 27. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG, Halilovic J, Stan-Ugbene O.
    Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
    [Abstract] [Full Text] [Related]

  • 28. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
    Smolen JS, Kay J, Matteson EL, Landewé R, Hsia EC, Xu S, Zhou Y, Doyle MK.
    Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769
    [Abstract] [Full Text] [Related]

  • 29. Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation.
    Kirkham BW, Wasko MC, Hsia EC, Fleischmann RM, Genovese MC, Matteson EL, Liu H, Rahman MU.
    Ann Rheum Dis; 2014 Jan; 73(1):161-9. PubMed ID: 23300117
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age.
    Tesser J, Kafka S, DeHoratius RJ, Xu S, Hsia EC, Turkiewicz A.
    Arthritis Res Ther; 2019 Aug 20; 21(1):190. PubMed ID: 31429794
    [Abstract] [Full Text] [Related]

  • 31. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.
    O'Dell JR, Curtis JR, Mikuls TR, Cofield SS, Bridges SL, Ranganath VK, Moreland LW, TEAR Trial Investigators.
    Arthritis Rheum; 2013 Aug 20; 65(8):1985-94. PubMed ID: 23686414
    [Abstract] [Full Text] [Related]

  • 32. Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial.
    Kremer JM, Rigby W, Singer NG, Birchwood C, Gill D, Reiss W, Pei J, Michalska M.
    Arthritis Rheumatol; 2018 Aug 20; 70(8):1200-1208. PubMed ID: 29575803
    [Abstract] [Full Text] [Related]

  • 33. Maintenance of efficacy and safety with subcutaneous golimumab in rheumatoid arthritis patients with low disease activity who previously received TNF inhibitors.
    Wakabayashi H, Inada H, Nishioka Y, Hasegawa M, Sudo A, Nishioka K.
    Clin Rheumatol; 2017 Apr 20; 36(4):941-946. PubMed ID: 27942977
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study.
    Genovese MC, Han C, Keystone EC, Hsia EC, Buchanan J, Gathany T, Murphy FT, Wu Z, Parasuraman S, Rahman MU.
    J Rheumatol; 2012 Jun 20; 39(6):1185-91. PubMed ID: 22505702
    [Abstract] [Full Text] [Related]

  • 36. Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritis.
    Emery P, Fleischmann RM, Hsia EC, Xu S, Zhou Y, Baker D.
    Clin Rheumatol; 2014 Sep 20; 33(9):1239-46. PubMed ID: 25005327
    [Abstract] [Full Text] [Related]

  • 37. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Keystone E, Heijde Dv, Mason D, Landewé R, Vollenhoven RV, Combe B, Emery P, Strand V, Mease P, Desai C, Pavelka K.
    Arthritis Rheum; 2008 Nov 20; 58(11):3319-29. PubMed ID: 18975346
    [Abstract] [Full Text] [Related]

  • 38. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.
    Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU.
    Arthritis Rheum; 2009 Aug 20; 60(8):2272-83. PubMed ID: 19644849
    [Abstract] [Full Text] [Related]

  • 39. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF, Westhovens R, Reed DM, Fanti L, Becker JC, Covucci A, Keystone EC.
    J Rheumatol; 2011 Nov 20; 38(11):2362-8. PubMed ID: 21885491
    [Abstract] [Full Text] [Related]

  • 40. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis.
    Taylor PC, Steuer A, Gruber J, McClinton C, Cosgrove DO, Blomley MJ, Marsters PA, Wagner CL, Maini RN.
    Arthritis Rheum; 2006 Jan 20; 54(1):47-53. PubMed ID: 16385521
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.